Salmeterol/fluticasone propionate combination

Drugs

Volumn 57, Issue 6, 1999, Pages 933-940

  Spencer, Caroline M ^a   Jarvis, Blair ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

BUDESONIDE; CORTICOSTEROID; FLUTICASONE PROPIONATE; HYDROCORTISONE; SALMETEROL;

ADRENAL SUPPRESSION; ASTHMA; CANDIDIASIS; CLINICAL TRIAL; COUGHING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DYSPHONIA; DYSPNEA; FORCED EXPIRATORY VOLUME; HEADACHE; HEART PALPITATION; HOARSENESS; HUMAN; HYDROCORTISONE BLOOD LEVEL; INHALATIONAL DRUG ADMINISTRATION; LUNG FUNCTION; OROPHARYNX; POWDER INHALER; QUALITY OF LIFE; REVIEW; TACHYCARDIA; THROAT DISEASE; TREMOR; VERTIGO;

ADMINISTRATION, INHALATION; ADOLESCENT; ADULT; ALBUTEROL; ANDROSTADIENES; ANTI-ASTHMATIC AGENTS; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHILD; CLINICAL TRIALS; DRUG COMBINATIONS; HUMANS; HYDROCORTISONE; NEBULIZERS AND VAPORIZERS;

EID: 0033007141     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199957060-00010     Document Type: Review

References (36)

1. 1. Greening AP, Ind PW, Northfield M, Allen & Hanburys Limited UK Study Group, et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 1994 Jul 23; 344 (8917): 219-24
2. 2. Woolcock A, Lundback B, Ringdal N, et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhlaed steroids. Am J Respir Crit Care Med 1996 May; 153 (5): 1481-8
3. 3. Ind PW, Dal NR, Colman N, et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma I: lung function and symptoms [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (Pt 2) Suppl.: A416
4. 4. Ind PW, Dal Negro R, Colman N, et al. Inhaled fluticasone propionate and salmeterol in moderate adult asthma II: exacerbations [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (Pt 2) Suppl.: 415
5. 5. Sly RM. New guidelines for diagnosis and management of asthma. Ann Allergy Asthma Immunol 1997 May; 78: 427-37
6. 6. National Institutes of Health. Global initiative for asthma. Global strategy for asthma management and prevention NHLB/ WHO workshop report [online]. Global Initiative for Asthma and National Heart, Lung and Blood Institute; 1995 Jan. Available from: URL: http://www.ginasthma.com/workshop/ default.html [Accessed 1999 May 5]
7. 7. Schlaeppi M, Edwards K, Fuller RW. Patient perception of the Diskus inhaler: a comparison with the Turbuhaler inhaler. Br J Clin Pract 1996 Jan-Feb; 50: 14-9
8. 8. Sharma RK, Edwards K, Hallett C, et al. Perception among paediatric patients of the Diskus® inhaler, a novel multidose powder inhaler for use in the treatment of asthma; comparison with the Turbuhaler® inhaler. Clin Drug Invest 1996; 11 (3): 145-53
9. 9. Adkins JC, McTavish D. Salmeterol: a review of its pharmacological properties and clinical efficacy in the management of children with asthma. Drugs 1997 Aug; 54: 331-54
10. 10. Holliday SM, Faulds D, Sorkin EM. Inhaled fluticasone propionate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in asthma. Drugs 1994 Feb; 47: 318-31
11. 11. Brogden RN, Faulds D. Salmeterol xinafoate: a review of its pharmacological properties and therapeutic potential in reversible obstructive airways disease. Drugs 1991; 42: 895-912
12. 12. Jarvis B, Faulds D. Inhaled fluticasone propionate: a review of its therapeutic efficacy at dosages <500 μg/day in adults and adolescents with mild to moderate asthma. Drugs 1994 May; 57: 769-803
13. 13. Dahl R. Salmeterol and fluticasone propionate in the treatment of asthma symptoms. Eur Resp Rev 1997 Aug; 7: 338-43
14. 14. Johnson M. Development of fluticasone propionate and comparison with other inhaled corticosteroids, J Allergy Clin Immunol 1998 Apr; 101 (Part 2) Suppl.: 434-9
15. 2-adrenergic receptor. J Biol Chem 1996 Sep; 271: 24029-35
16. 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax 1988; 43 (9): 674-8
17. 2-adrenergic bronchodilators and anti-inflammatory steroids in asthma. J Pharmaceut Med 1996; 6 (1-2): 5-16
18. 18. Chung KF. The complementary role of glucocorticosteroids and long-acting β-adrenergic agonists. Allergy 1998; 53 Suppl. 42: 7-13
19. 2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999 Jan; 274 (2): 1005-10
20. 20. Seretide Monograph. Glaxo Wellcome UK. 1998
21. 21. Man CY, Kirby SM, McRae J, et al. Systemic pharmacodynamic effects of salmeterol in the salmeterol/FP combination Diskus™ inhaler [abstract no. P1073]. Eur Respir J 1996 Sep; 9 Suppl. 23: 164
22. 22 Edwards T, Gross G, Mitchell D, et al. The salmeterol xinafoate/fluticasone propionate dry powder combination product via Diskus® inhaler improves asthma control compared to salmeterol xinafoate or fluticasone propionate alone [abstract]. Am J Respir Crit Care Med 1998 Mar; 157 (Pt 2) Suppl.: A414
23. 23. Wolfe J, Bell T, Raphael G, et al. Efficacy of the salmeterol/ fluticasone propionate dry powder combination product in the Diskus® a stratified study in patients on salmeterol alone or inhaled corticosteroids [abstract]. J Allergy Clin Immunol 1999 Jan; 103 Pt 2: 228
24. 24. Nathan R, LaForce C, Mitchell D, et al. The salmeterol/ fluticasone propionate combination (50/100mcg) via Diskus® has a rapid onset of effect in asthma patients on salmeterol or inhaled corticosteroids. Presented at the American Throacic Society Meeting; 1999 Apr 23-28; San Diego (CA)
25. 25. Lumry W, Windom H, Mendelson L, et al. The salmeterol/ fluticasone propionate (50/250mcg) dry powder combination Diskus® has a faster onset of effect compared with salmeterol or fluticasone propionate in patients with asthma. J Allergy Clin Immunol 1999; 103 Pt 2: 132
26. 26. While M, Shapiro G, Taylor J, et al. The salmeterol xinafoate/fluticasone propionate dry powder combination product via Diskus® inhaler improves asthma control compared to the individual products in patients previously treated with inhaled corticosteroids. Presented at the American Throacic Society Meeting; 1999 Apr 23-28; San Diego (CA)
27. 27. Aubier M, Pieters WR, Schlösser NJJ, et al. Salmeterol/ fluticasone propionate (50/500 μg) in combination in a Discus® inhaler (Seretide®) is effective and safe in the treatment of steroid-dependent asthma. GlaxoWellcome (in press)
28. 28. Pieters WR, Sleinmetz K-O, Aubier M, et al. Effectiveness of a new salmeterol/fluticasone propionate (50/500 μg) combination inhaler in patients with reversible airways obstruction [abstract no. P0329]. Eur Respir J 1998 Sep; 12 Suppl. 28: 35s
29. 29. Bateman ED, Britton M, Carrillo J, et al. Salmeterol/fluticasone combination inhaler; a new, effective and well tolerated treatment for asthma. Clin Drug Invest 1998 Sep; 16: 193-201
30. 30. Chapman KR, Ringdal N, Backer V, et al. Salmeterol and fluticasone propionate (50/250μg) administered via combination Discus inhaler; as effective as when given via separate Diskus inhalers. Can Respir J 1999; 6 (1): 45-51
31. 31. Johansson G, Melvor RA, Purello D'Ambrosio F, et al. Seretide (salmeterol 50mcg/fluticasone propionate 100mcg bid) compared with budesonide (400mcg bid) in mild 10 moderate asthma. Presented at the American Throacic Society Meeting; 1999 Apr 23-28; San Diego (CA)
32. 32. Jenkins C, Woolcock AJ, Saarelainen P, et al. A comparison of Seretide™ (salmeterol 50mcg/fluticasone propionate 250mcg bid) with budesonide (800mcg) bid in moderate asthma. Presented at the American Throacic Society Meeting; 1999 Apr 23-28; San Diego (CA)
33. 33. Reese PR, Mahajan P, Woodring A, Salmeterol/fluticasone propionate combination product improves quality of life in asthma patients [abstract no. P0325]. Eur Respir J 1998 Sep; 12 Suppl. 28: 35s
34. 34. Reese PR, Mather DB, Mahajan P, et al. Combination of salmeterol/fluticasone propionate via Diskus® improves quality of life in asthma patients [abstract]. J Allergy Clin Immunol 1999 Jan; 103 Pt 2: 69
35. 35. van den Berg NJ, Ossip M, Hederos CA, et al. Combined salmeterol xinafoate and fluticasone propionate (50/100μg strength) bd via one discus™ (accuhaler™) inhaler compared with salmeterol xinafoate 50μg and fluticasone propionate 100 μg bd via two separate discus inhalers [abstract no. P1108]. Eur Respir J 1998; 12 Suppl. 28: 157
36. 36. Zimmerman B, Gold M, Wherrett D, et al. Adrenal suppression in two patients with asthma treated with low doses of the inhaled steroid fluticasone propionate. J Allergy Clin Immunol 1998 Mar; 101:425-6